All GLG News Analyses Filed Under: Oncology

The key to the current study is whether sequential gene expression profiling of hair follicles before and during the course of a patient's treatment can be 'linked to changes in tumours' and act therefore 'to determine drug exposure, toxicity and dose response'. The authors, and indeed previous...

GSK's oral topotecan was favorably reviewed in Europe for treatment of recurrent small cell cancer. IV topotecan is used in ovarian cancer , sarcomas, an rarely in hematological malignancies. The indication is quite narrow and oral use is complicated by lack of re-imbursement and poor patient...

In a phase II trial , Pfizer's Sutent produced an overall response arte of 11 % as second line treatment for patients with non-small cell lung cancer. The response rates is similar to approved agents for recurrent patients with an oral "targeted " drug and favorable safety profile. The role would be...

Sutent is demonstrating some activity in Lung cancer Sutent is unique in this regard versus other TKIs ? I would focus on the FELT for obvious reasons

Hematde is a new ESA with potential benefit over older ESAs hematide may look especially god coming off some of the recent FDA concerns abiut ESAs

New oral agents to replae previous iv meds will not likelty succeed in near future in US patient's are less compliant with oral meds, even for cancer

An oral version of Topotecan that can be used 2nd line in SCLCA. Impact?

Intron-A is currently the only FDA approved medicine to treat melanoma patients without active disease but at high risk for future recurrence. On March 12, 2008, the Oncology Drug Advisory Committee (ODAC) will discuss newly available data on the effectiveness and safety profile of PEG Intron, a longer...

Takeda is collaborating with Effamax to conduct a phase I trial investigating a new erythropoeitin stimulating agent  ( ESA) in anemic patients with refractory solid tumors receiving chemotherapy. The study is well designed and if the new agent has efficacy of Aranesp ( Amgen) and Procrit ( J&...

Preliminarily appears to be effective in Non Small Cell Carcinoma of the Lung (NSCLCA). Overall response rates are comparable to standard second line agent efficacy, and its ORAL.